Benzenemethanamine, 4-(cyclopropylmethoxy)-alpha-methyl- | 221670-73-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: Benzenemethanamine, 4-(cyclopropylmethoxy)-alpha-methyl-
• 英文别名: 1-[4-(cyclopropylmethoxy)phenyl]ethanamine
• CAS: 221670-73-1
• 化学式: C₁₂H₁₇NO
• 分子量: 191.27
• InChiKey: FYMNFSMFSVCRJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Benzenemethanamine, 4-(cyclopropylmethoxy)-alpha-methyl- 、 2-[(5-methyl-2-oxo-1H-pyrimidin-4-yl)sulfanyl]acetic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以0.09 g的产率得到N-[1-[4-(cyclopropylmethoxy)phenyl]ethyl]-2-[(5-methyl-2-oxo-1H-pyrimidin-4-yl)sulfanyl]acetamide
  参考文献：
  名称：

  RNA DEGRADERS AND USES THEREOF

  摘要：

  The present invention includes compounds and compositions, and methods of use thereof for modulating an RNA transcript, or a precursor, isoform, fragment, or mutant thereof by degradation of the RNA transcript via recruitment or binding of one or more decay factors (e.g., an RNA binding protein).

  公开号：

  WO2024112918A1
• 作为产物：
  描述：

  4-(环丙基甲氧基)苯甲醛 在 盐酸 、 叠氮磷酸二苯酯 、 palladium on activated charcoal 、 氢气 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 27.0h， 生成 Benzenemethanamine, 4-(cyclopropylmethoxy)-alpha-methyl-
  参考文献：
  名称：

  RNA DEGRADERS AND USES THEREOF

  摘要：

  The present invention includes compounds and compositions, and methods of use thereof for modulating an RNA transcript, or a precursor, isoform, fragment, or mutant thereof by degradation of the RNA transcript via recruitment or binding of one or more decay factors (e.g., an RNA binding protein).

  公开号：

  WO2024112918A1

文献信息

• 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
  申请人：NOVARTIS AG

  公开号：US10112931B2

  公开（公告）日：2018-10-30

  The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

  本发明涉及式 (I)： 或其药学上可接受的盐，其中 R1、R2a、R2b 和 R3-R7 在此处。本发明还涉及含有式（I）化合物的组合物，以及此类化合物在抑制具有新变态活性的突变 IDH 蛋白中的用途。本发明进一步涉及式（I）化合物在治疗与此类突变IDH蛋白相关的疾病或紊乱中的用途，包括但不限于细胞增殖紊乱，如癌症。
• Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same
  申请人：Yuhan Corporation

  公开号：US10383859B2

  公开（公告）日：2019-08-20

  The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.

  本发明提供了一种苯并[d]噻唑衍生物或其药学上可接受的盐、其制备工艺以及包含其的药物组合物。苯并[d]噻唑衍生物或其药学上可接受的盐可以选择性地抑制 KRS 与层粘连蛋白受体（LR）之间的蛋白-蛋白相互作用，从而抑制癌细胞的迁移。因此，苯并[d]噻唑衍生物或其药学上可接受的盐可用于预防或治疗与癌细胞转移相关的疾病。
• BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME
  申请人：Yuhan Corporation

  公开号：EP3483149B1

  公开（公告）日：2021-01-13
• 3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH
  申请人：NOVARTIS AG

  公开号：US20180051015A1

  公开（公告）日：2018-02-22

  The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2a , R 2b and R 3 -R 7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
• Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same
  申请人：Yuhan Corporation

  公开号：US20190142809A1

  公开（公告）日：2019-05-16

  The present invention provides a benzo[d]thiazole derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, and a pharmaceutical composition comprising the same. The benzo[d]thiazole derivative or its pharmaceutically acceptable salt can selectively inhibit the protein-protein interaction between KRS and a laminin receptor (LR), thereby inhibiting migration of cancer cells. Therefore, the benzo[d]thiazole derivative or its pharmaceutically acceptable salt may be usefully applied for preventing or treating the diseases associated with cancer cell metastasis.